



NEWS RELEASE  
FOR IMMEDIATE RELEASE

TSX: AMF

## **AMORFIX EXTENDS WARRANT TERM BY ONE YEAR**

**TORONTO**, Ontario – February 20, 2009 – Amorfix Life Sciences Ltd. announced that it has extended by one year the term of 4,462,521 common share purchase warrants (the "Warrants"), which are exercisable for one common share of Amorfix at an exercise price of \$1.95 and were issued on March 8, 2007 as part of a private placement.

Amorfix has received TSX acceptance, subject to satisfying customary conditions, to extend (the "Extension") the expiry date of the Warrants by one year (from March 8, 2009) to March 8, 2010. The Extension is subject to an earlier expiry in the event that the volume-weighted average price of Amorfix's common shares on the TSX over a period of 10 consecutive trading days exceeds \$2.50, in which case Amorfix may give notice to holders to accelerate the expiry to a date which is not less than 30 calendar days after such notice is sent to the holders.

The effective date of the Extension will be from the current expiry date of March 8, 2009.

25,000 Warrants held by insiders are included in the Extension, subject to disinterested shareholder approval under TSX policies. Amorfix intends to seek such approval at its next AGM. Until Amorfix receives the required disinterested shareholder approval of the Extension, the Warrants held by its insiders cannot be exercised.

### **About Amorfix**

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer's Disease, Parkinson's Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

*This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other*

*factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

- 30 -

**For more information, please contact:**

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6959 Fax: (416) 847-6899 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6929 Fax: (416) 847-6899 james.parsons@amorfix.com
---	---